Form 4: Relay Therapeutics Director Laura Shawver Acquires Stock Options

Director Laura Shawver of Relay Therapeutics, Inc. was granted stock options for 102,225 shares on June 3, 2024.

Summary

• Laura Shawver, a director at Relay Therapeutics, Inc., was granted stock options to purchase 102,225 shares of the company's common stock.
• The transaction occurred on June 3, 2024.
• The exercise price of the stock options is $6.79 per share.
• The options vest in full on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders following the grant date.
• The options expire on June 2, 2034.
• Following the transaction, Shawver directly owns options for 102,225 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options, which is generally viewed as a positive sign of aligning director interests with shareholders. It's a neutral event, but indicates ongoing commitment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. This grant is typical for directors in similar companies.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The size of the grant is within the typical range for directors at companies with similar market capitalization to Relay Therapeutics.
• Vesting schedules of one year or until the next annual meeting are also common practice.

Key Dates